Keyword: Jazz Pharmaceuticals

6. Defitelio

Upon its March approval, Jazz Pharma’s Defitelio became the first marketed drug to treat severe hepatic veno-occlusive disease in the U.S., providing a significant therapeutic advance to a small group of patients.